Claims for Patent: 10,167,486

Summary for Patent: 10,167,486

Title:	Vectors and methods for long-term immune evasion to prolong transplant viability
Abstract:	A kit for altering allogeneic human cells for a human recipient where the kit includes a set of lentivirus vectors where each of the lentivirus vectors expresses a sequence targeting a consensus conserved nucleic acid sequence, which when expressed in cells, functions as a negative modulator for nucleic acid encoding a domain having a mismatch in an HLA protein and where the set of lentivirus vectors includes individual lentivirus vectors that correspond to individual HLA mismatches for a set of HLA mismatches that consist of HLA Class I mismatches and at least one HLA Class II mismatch and where the kit is for treatment of human cells by an appropriate subset of the set of lentivirus vectors based at least in part on a determined subset of the set of HLA mismatches between a human donor and a human recipient or between human cells and a human recipient.
Inventor(s):	Cicciarelli; James C. (Rolling Hills, CA), Kasahara; Noriyuki (Los Angeles, CA), Logg; Christopher R. (South Pasedena, CA)
Assignee:	NATIONAL INSTITUTE OF TRANSPLANTATION FOUNDATION (Los Angeles, CA)
Application Number:	15/621,880
Patent Claims:	1. A kit for altering allogeneic human cells for a human recipient, the kit comprising: a set of lentivirus vectors wherein each of the lentivirus vectors expresses a sequence targeting a consensus conserved nucleic acid sequence, which when expressed in cells, functions as a negative modulator for nucleic acid encoding a domain having a mismatch in an HLA protein and wherein the set of lentivirus vectors comprises individual lentivirus vectors that correspond to individual HLA mismatches for a set of HLA mismatches that consist of HLA Class I mismatches and at least one HLA Class II mismatch; wherein the kit is for treatment of human cells by an appropriate subset of the set of lentivirus vectors based at least in part on a determined subset of the set of HLA mismatches between a human donor and a human recipient or between human cells and a human recipient. 2. The kit of claim 1 wherein the sequence comprises an siRNA sequence. 3. The kit of claim 1 wherein the at least one of the lentivirus vectors comprises a marker gene cassette for expressing a fluorescent protein for detection of cells transduced by the at least one of the lentivirus vectors. 4. The kit of claim 3 comprising another one of the lentivirus vectors constructed without the marker gene cassette. 5. The kit of claim 1 comprising an additional composition formed by contacting the at least one of the lentivirus vectors with cells wherein the additional composition comprises at least some of the contacted cells or a population of cells derived from at least some of the contacted cells. 6. The kit of claim 5 wherein the additional composition comprises one or more additional therapeutic agents. 7. The kit of claim 6 wherein the one or more additional therapeutic agents comprises a member selected from a group consisting of growth factors, anti-inflammatory agents, vasopressor agents, collagenase inhibitors, topical steroids, matrix metalloproteinase inhibitors, ascorbates, angiotensin II, angiotensin III, calreticulin, tetracyclines, fibronectin, collagen, thrombospondin, transforming growth factors (TGF), keratinocyte growth factor (KGF), fibroblast growth factor (FGF), insulin-like growth factors (IGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), neu differentiation factor (NDF), hepatocyte growth factor (HGF), B vitamins, and hyaluronic acid. 8. The kit of claim 1 comprising lentivirus vector compositions wherein the lentivirus vector compositions each comprise a different level of its respective lentivirus vector. 9. The kit of claim 1 wherein the lentivirus vectors comprise the lentivirus vectors as compositions in a dosage unit form. 10. The kit of claim 9 comprising the dosage unit form being based on an animal model. 11. The kit of claim 1 comprising a range of dosages for the lentivirus vectors that is based at least in part on data obtained from an animal study. 12. The kit of claim 1 wherein the HLA Class I mismatches and the at least one HLA Class II mismatch consists of an HLA-A mismatch, a HLA-B mismatch, a HLA-C mismatch, a HLA-G mismatch, a HLA-DR mismatch, a HLA-DQ mismatch and a HLA-DP mismatch. 13. The kit of claim 1 wherein the treatment of human cells by the appropriate subset of the set of lentivirus vectors comprises at least one permanently integratable lentivirus vector.

Details for Patent 10,167,486

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2024-05-18